Aligos Therapeutics, developing several different hep B and NASH treatments, files for $100M IPO raise
Another biotech filed to go public late Friday as the 2020 IPO party rages on.
Aligos Therapeutics, focusing on chronic hepatitis B and NASH, submitted its S-1 paperwork to the SEC with a goal of raising $100 million. The company’s lead candidate is known as a STOPS molecule, or an S-antigen transport-inhibiting oligonucleotide polymer, and started a Phase I study for CHB in August.
Through late August, the industry as a whole had raised $11 billion-plus across four dozen IPOs, per independent analyst Brad Loncar, surpassing the amount from all of 2019.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.